NICE accepts golimumab in rheumatoid arthritis

NICE has recommended golimumab (Simponi), in combination with methotrexate, as another option for the treatment of active rheumatoid arthritis. Like other tumour necrosis factor (TNF) inhibitors, it can be considered for use in patients with:

  • a disease activity score greater than 5.1 on two separate occasions at least 1 month apart, who have undergone trials of two conventional DMARDs, including methotrexate (unless contraindicated), or
  • severe rheumatoid arthritis, who have inadequately responded to other DMARDs, including at least one TNF inhibitor, and for whom rituximab is inappropriate.

NICE approval of golimumab is contingent on the manufacturer supplying the 100mg dose, which should be considered for use in patients >100kg, at the same price as the 50mg dose.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Products coming soon - live tracker

EXCLUSIVE TO SUBSCRIBERS Monitor forthcoming UK drug...

Drug shortages - live tracker

EXCLUSIVE TO SUBSCRIBERS Use our constantly updated...

Back of man's head suffering from alopecia

Alopecia drug to be available on the NHS

In an NHS first, NICE is recommending ritlecitinib...

Stressed male GP with hand on head